Literature DB >> 8804242

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Y Nomoto1, Y Kawaguchi, H Kubo, H Hirano, S Sakai, K Kurokawa.   

Abstract

Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) who developed sclerosing encapsulating peritonitis (SEP) were retrospectively studied in 130 centers in Japan. Among 6,923 patients undergoing CAPD between 1980 and 1994 only 62 (0.9%) given CAPD developed SEP. There were 38 men and 24 women, ranging in age from 20 to 87 years (average age, 48.3 years). These 62 patients developed SEP 10 to 138 months (average, 65.4 months) after starting CAPD. The average frequency of peritonitis before developing SEP was 3.3 times. Five of the 62 patients with SEP had no history of peritonitis, and 27 (43.5%) of them died of various causes in the study period. The major causes of death were almost invariably related to problems concerning bowel obstruction or complications of surgery, such as malnutrition or septicemia. It was concluded that SEP is one of the most serious complications of CAPD, and constant surveillance is necessary to detect SEP in patients during CAPD.

Entities:  

Mesh:

Year:  1996        PMID: 8804242     DOI: 10.1016/s0272-6386(96)90501-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

1.  Towards standardized reporting in studies of encapsulating peritoneal sclerosis.

Authors:  Mark Lambie; Niko Braun; Simon J Davies
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

Review 2.  Encapsulating peritoneal sclerosis in children.

Authors:  Constantinos J Stefanidis; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-11-21       Impact factor: 3.714

3.  Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis.

Authors:  Yasushi Otsuka; Masaaki Nakayama; Masato Ikeda; Ali M Sherif; Keitaro Yokoyama; Hiroyasu Yamamoto; Yoshindo Kawaguchi
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

4.  No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis.

Authors:  Guido Garosi; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

5.  Cocoon abdomen after chronic peritoneal dialysis.

Authors:  Philip Edmundson; Claire Adkins; Bruce Smith
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-26

Review 6.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

7.  Peritoneal cocoon capsulotomy--an alternative surgical approach in treating encapsulating peritoneal sclerosis.

Authors:  Marc Gingell-Littlejohn; Faisal Hanif; Brian Junor; Marc Clancy; Enric Murio
Journal:  Perit Dial Int       Date:  2013 May-Jun       Impact factor: 1.756

8.  Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.

Authors:  Erika De Sousa-Amorim; Gloria Del Peso; M Auxiliadora Bajo; Laura Alvarez; Marta Ossorio; Fernando Gil; Teresa Bellon; Rafael Selgas
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 9.  Long-term peritoneal dialysis and encapsulating peritoneal sclerosis in children.

Authors:  Masataka Honda; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

10.  Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea.

Authors:  Beom Seok Kim; Hoon Young Choi; Dong-Ryeol Ryu; Tae Hyun Yoo; Hyeong Cheon Park; Shin Wook Kang; Kyu Hun Choi; Sung Kyu Ha; Dae Suk Han; Ho Yung Lee
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.